Lagging Supply Chain Causing Medicine Shortages in Maldives, Says State Pharma Chief

The medicine shortages currently affecting patients across the Maldives are the direct result of a supply chain that failed to keep pace with the rapid expansion of the country's health sector, according to State Pharma. Dr. Shah Abdulla Mahir, Managing Director of the State Pharmaceutical and Medical Supply Corporation Limited (State Pharma), stated that addressing the structural deficiencies preventing public access to prescribed medications is now the company's primary mandate. Since beginning the fulfillment of prescriptions in April, the state-run firm has already delivered medications to over 1,000 citizens. Dr. Mahir highlighted several critical bottlenecks hindering the process, including complex bureaucratic hurdles, stringent requirements for temperature-regulated storage, and difficulties in international sourcing. He also pointed to a lack of institutional uniformity, noting that the system urgently requires the standardization of billing codes and the reconciliation of various marketplace brands to function efficiently. "From the moment a prescription is issued to a patient, the required medication must be readily accessible," Dr. Mahir remarked. Internal research conducted by the corporation revealed a significant gap in the system: only 25 percent of medications used nationwide are currently registered with the State Trading Organisation (STO). To combat these shortages and stabilize retail prices, State Pharma is partnering with private entities and implementing preemptive procurement strategies to build robust stockpiles. According to Dr. Mahir, the current crisis is a reflection of a developmental imbalance where advanced clinical capabilities have outstripped the logistical backbone. He explained that these issues emerged because structural systems and logistical protocols remained unorganized while the broader healthcare system underwent rapid growth. He pledged that visible improvements in medicine accessibility will be evident within the next six months.